Platelet poor plasma gel combined with amnion improves the therapeutic effects of human umbilical cord-derived mesenchymal stem cells on wound healing in rats

Abstract

The aim of the present study was to investigate the efficacy of human umbilical cord‑derived mesenchymal stem cell (HUMSCs) embedded in platelet poor plasma (PPP) gel combined with amnion (PPPA) in improving wound healing on Sprague‑Dawley (SD) rats. HUMSCs were cultured and labeled with chloromethylbenzamido‑1,1'‑dioctadecyl‑3,3,3'3'‑tetramethylindocarbocyanine perchlorate (CM‑DiI) on their third passage. The expression levels of growth factors of HUMSCs in PPPA were assessed by ELISA. Full‑thickness excisional skin wounds were induced in 36 male SD rats, which were treated with PPPA grafted with HUMSCs (PPPAC), PPPA, or HUMSC or PBS injection. The degree of healing and the distribution of labeled HUMSCs in the wound were evaluated by hematoxylin and eosin (H&E) staining and immunofluorescence. On day 14 post‑surgery, wound healing in PPPAC‑treated rats was significantly higher than the PPPA group, compared with rats treated with HUMSCs alone and control rats (P<0.05 and P<0.01, respectively). H&E staining showed that morphology and thickness of the epidermis in the PPPAC group was similar to that of healthy skin. ELISA revealed that levels of growth factors of HUMSCs in PPPAC were higher than in monolayer cells. In conclusion, PPPA can modify growth factor expression levels of HUMSCs and improve the efficiency of HUMSCs in the healing of full thickness wounds in rats.

Assessment of the efficacy and safety of platelet poor plasma gel as autologous dermal filler for facial rejuvenation

“…The immediate significant efficacy of plasma gel injection as a dermal filler could be explained by the direct volumetric filling effect of the gel formula that contains denaturized gelled proteins and fibrin bundles providing its constant stability and volume . In addition, platelets work through the degranulation of its α‐granules, which contain presynthesized growth factors.…”

“…Ten milliliter of venous blood sample was taken from each participant under aseptic conditions and then collected in a sterile vacuum tube (10.0 mL) equipped with premeasured amounts of anticoagulant citrate dextrose solution . Each blood sample was centrifuged at 320 × g , for 15 minutes at 4°C, resulting in the following three layers: the lower layer composed of red blood cells, the middle layer composed of white blood cells (the buffy coat), and the upper layer composed of plasma.…”

“…Activation of platelet poor plasma (PPP) by adding a clotting cascade activator, such as calcium gluconate, calcium chloride or thrombin, and/or thermal treatment, gives rise to the formation of a gelatinous material known as “plasma gel” . It contains fibrin that provides the formula with greater consistency and resistance than ordinary platelet‐rich plasma (PRP) or PPP, and gelled proteins that provide constant stability and volume .…”

Autologous noncultured, nontrypsinized melanocyte‐keratinocyte graft homogenized in plasma gel followed by narrow‐band ultraviolet B therapy for stable vitiligo: A novel technique

“…Also, fibrin forms a mesh structure inside the platelet poor plasma (PPP) gel and provides three-dimensional (3D) culture conditions for cells and promotes wound scabbing. 11,12 Narrow band ultraviolet B (NB-UVB) is the most widely used phototherapy in vitiligo treatment with the highest efficacy. 13 It damps the cytotoxic T cells effect on targeted melanocytes which leads to disappearance of melanin.…”

Comment Regarding Article “Quantitative T2 MRI Mapping and 12-Month Follow-up in a Randomized, Blinded, Placebo Controlled Trial of Bone Marrow Aspiration and Concentration for Osteoarthritis of the Knees”

“…Among the aims of a pilot trial, there is the collection of data to perform a power analysis to calculate the sample size of a larger RCT, and the aforementioned clinical scores are the most commonly used to this purpose, so their use seems recommendable in the setting of a pilot trial. (2) The addition of platelet-poor plasma (PPP) to the BMAC before intraarticular injection, which could represent a confounding factor since PPP may exert its own biologic actions 4,5 and therefore limit the understanding of the contribution of BMAC itself. Last, the choice of treating patients affected by bilateral knee osteoarthritis seems also questionable since, as shown in previous studies, 6 clinical questionnaires cannot independently score both knees of one patient as they were 2 knees of 2 different patients: in bilateral osteoarthritis, one knee might affect the contralateral one and therefore this effect should be taken into account when performing the statistical evaluation, and a test with "correction for patient" (e.g., generalized linear model with the patient as a random effect) should be used.…”